Asthma Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

Asthma pipeline constitutes 100+ key companies continuously working towards developing 100+ Asthma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Asthma Overview
Asthma is a chronic disease that affects the airways. It is characterized by inflammation and spasm of the airways. The airways are tubes that carry air in and out of the lungs. If a person has asthma, the inside walls of the airways become sore and swollen. The air passages in the lungs become narrow due to inflammation and tightening of the muscles around the small airways. This causes asthma symptoms: cough, wheeze, shortness of breath, and chest tightness. The diagnosis and management of Asthma is challenging and complex, and requires the expertise of interprofessional team members who are familiar with all aspects of its evaluation and treatment.

"Asthma Pipeline Insight, 2022" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Asthma Market.

The Asthma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Asthma Pipeline Report: https://www.delveinsight.com/report-store/asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

• Companies across the globe are diligently working toward developing novel Asthma treatment therapies with a considerable amount of success over the years. Asthma Key players such as - Tarus therapeutics, Lanier Biotherapeutics, Landos Biopharma, KeyMed Biosciences, HoffmanLa-Roche, Kinaset therapeutics, Chia Tai Tianqing Pharmaceutical Group, Sterna Biologics, Aldeyra Therapeutics, GlaxoSmithKline, AstraZeneca, Avillion LLP, and others, are developing therapies for the Asthma treatment
• Asthma Emerging therapies such as - Research programme: A2BR inhibitors, LNR 125.38, LABP-73, CM326, RG6314, KN-002, TQC2731, SB010, ADX-629, GSK3511294, BGF MDI, PT027, and others are expected to have a significant impact on the Asthma market in the coming years.
• In January 2020, Avillion initiated a multicenter, randomized, double-blind, single-dose, placebo-controlled, 2-period, crossover study to evaluate the efficacy and safety of budesonide/albuterol metered-dose inhaler (BDA MDI/PT027) as compared with a placebo metered-dose inhaler (placebo MDI) on exercise-induced bronchoconstriction (EIB) in adult and adolescent subjects with asthma
• In May 2022, Avillion LLP, announced that the US Food and Drug Administration (FDA) has accepted for filing Avillion's New Drug Application (NDA) for AstraZeneca's PT027. The proposed indication is for the as-needed treatment or prevention of bronchoconstriction and for the prevention of exacerbations in patients with asthma 4 years of age and older. The NDA submission is based on data from studies conducted by AstraZeneca and Avillion to assess the safety and efficacy of PT027

Asthma Pipeline Therapeutics Assessment
• Asthma Assessment by Product Type
• Asthma By Stage and Product Type
• Asthma Assessment by Route of Administration
• Asthma By Stage and Route of Administration
• Asthma Assessment by Molecule Type
• Asthma by Stage and Molecule Type

DelveInsight's Asthma Report covers around 100+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Emerging Asthma Drugs Under Different Phases of Clinical Development Include:
• Research programme: A2BR inhibitors: Tarus therapeutics
• LNR 125.38: Lanier Biotherapeutics
• LABP-73: Landos Biopharma
• CM326: KeyMed Biosciences
• RG6314: HoffmanLa-Roche
• KN-002: Kinaset therapeutics
• TQC2731: Chia Tai Tianqing Pharmaceutical Group
• SB010: Sterna Biologics
• ADX-629: Aldeyra Therapeutics
• GSK3511294: GlaxoSmithKline
• BGF MDI: AstraZeneca
• PT027: Avillion LLP

Asthma Pipeline Analysis:

The Asthma pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the Asthma treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Asthma Treatment.
• Asthma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Asthma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Asthma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Asthma product details are provided in the report. Download the Asthma pipeline report to learn more about the emerging Asthma therapies at:
https://www.delveinsight.com/sample-request/asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Asthma Pipeline Market Drivers
• Increasing prevalence of asthma worldwide
• R&D focus towards developing novel therapies for asthma
• Increasing healthcare expenditures

Asthma Pipeline Market Barriers
• High cost of asthma medications
• Inadequate knowledge/Less awareness in under-emerging economies
• Lack of effective and proven therapies for asthma

Get a Free Sample PDF Report to know more about Asthma Pipeline Assessment- https://www.delveinsight.com/sample-request/asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Scope of Asthma Pipeline Drug Insight
• Coverage: Global
• Key Asthma Companies: Tarus therapeutics, Lanier Biotherapeutics, Landos Biopharma, KeyMed Biosciences, HoffmanLa-Roche, Kinaset therapeutics, Chia Tai Tianqing Pharmaceutical Group, Sterna Biologics, Aldeyra Therapeutics, GlaxoSmithKline, AstraZeneca, Avillion LLP, and others
• Key Asthma Therapies: Research programme: A2BR inhibitors, LNR 125.38, LABP-73, CM326, RG6314, KN-002, TQC2731, SB010, ADX-629, GSK3511294, BGF MDI, PT027, and others
• Asthma Therapeutic Assessment: Asthma current marketed and Asthma emerging therapies
• Asthma Market Dynamics: Asthma market drivers and Asthma market barriers

Request for Sample PDF Report for Asthma Pipeline Assessment and clinical trials- https://www.delveinsight.com/sample-request/asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1 Asthma Report Introduction
2 Asthma Executive Summary
3 Asthma Overview
4 Asthma- Analytical Perspective In-depth Commercial Assessment
5 Asthma Pipeline Therapeutics
6 Asthma Late Stage Products (Phase II/III)
7 Asthma Mid Stage Products (Phase II)
8 Asthma Early Stage Products (Phase I)
9 Asthma Preclinical Stage Products
10 Asthma Therapeutics Assessment
11 Asthma Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Asthma Key Companies
14 Asthma Key Products
15 Asthma Unmet Needs
16 Asthma Market Drivers and Barriers
17 Asthma Future Perspectives and Conclusion
18 Asthma Analyst Views
19 Appendix
20 About DelveInsight

Download Sample PDF Report to know more about Asthma drugs and therapies- https://www.delveinsight.com/sample-request/asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Related Reports:

Asthma Market https://www.delveinsight.com/report-store/asthma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Asthma-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Asthma Epidemiology https://www.delveinsight.com/report-store/asthma-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Asthma Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Trending Reports:

Ventricular Assist Devices Market https://www.delveinsight.com/report-store/ventricular-assist-devices-vad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"DelveInsight's 'Ventricular Assist Devices (VAD) Market Insight, Competitive Landscape and Market Forecast - 2027' report delivers an in-depth understanding of Ventricular Assist Devices and the historical and forecasted Ventricular Assist Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Vein Illumination Devices Market https://www.delveinsight.com/report-store/vein-illumination-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

DelveInsight's 'Vein Illumination Devices - Market Insight, Competitive Landscape and Market Forecast, 2027' report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Basal Cell Carcinoma (Basal Cell Epithelioma) Market
https://www.delveinsight.com/report-store/basal-cell-carcinoma-basal-cell-epithelioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

DelveInsight's "Basal Cell Carcinoma (Basal Cell Epithelioma) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Basal Cell Carcinoma (Basal Cell Epithelioma), historical and forecasted epidemiology as well as the Basal Cell Carcinoma (Basal Cell Epithelioma) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Media Contact

Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.